New Jersey A4699 requires health insurance carriers to cover genetic testing after a diagnosis of pancreatic cancer.

New Jersey A4699 mandates that health insurance carriers cover genetic testing for individuals diagnosed with pancreatic adenocarcinoma. This includes group policies, small employer health benefits plans, individual health benefits plans, and contracts from the School Employees’ Health Benefits Commission and the State Health Benefits Commission. Genetic testing, defined as analyzing an individual’s DNA, RNA, chromosomes, or proteins to identify genetic changes or mutations, will be covered to the same extent as any other medical condition.

New Jersey A4699 requires health insurance carriers to cover genetic testing after a diagnosis of pancreatic cancer.

New Jersey A4699 mandates that health insurance carriers cover genetic testing for individuals diagnosed with pancreatic adenocarcinoma. This includes group policies, small employer health benefits plans, individual health benefits plans, and contracts from the School Employees’ Health Benefits Commission and the State Health Benefits Commission. Genetic testing, defined as analyzing an individual’s DNA, RNA, chromosomes, or proteins to identify genetic changes or mutations, will be covered to the same extent as any other medical condition.